Paclitaxel for AIDS-associated Kaposi’s sarcoma

References

• Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, Paul WE. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nature Med. 8(4), 319–323 (2002).
   PubMedGoogle Scholar
• Boshoff C, Weiss R. AIDS-related malignancies. Nature Rev. Cancer 2(5), 373–82 (2002).
   PubMedGoogle Scholar
• Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nature Rev. Cancer 4(11), 861–875 (2004).
   PubMedGoogle Scholar
• Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335, 123–128 (1990).
   PubMedGoogle Scholar
• Beral V, Bull D, Darby S et al. Risk of Kaposi’s sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet 339, 632–635 (1992).
   PubMed Web of Science ®Google Scholar
• Chang Y, Cesarman E, Pessin MS et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266(5192), 1865–1869 (1994).
   PubMed Web of Science ®Google Scholar
• Russo JJ, Bohenzky RA, Chien MC et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl Acad. Sci. USA 93(25), 14862–14867 (1996).
   PubMed Web of Science ®Google Scholar
• Carroll PA, Brazeau E, Lagunoff M. Kaposi’s sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 328(1), 7–18 (2004).
   PubMedGoogle Scholar
• Gold JA, Rom WN, Harkin TJ. Significance of abnormal chest radiograph findings in patients with HIV-1 infection without respiratory symptoms. Chest 121(5), 1472–1477 (2002).
   PubMedGoogle Scholar
• Hannon FB, Easterbrook PJ, Padley S, Boag F, Goodall R, Phillips RH. Bronchopulmonary Kaposi’s sarcoma in 106 HIV-1 infected patients. Int. J. STD AIDS 9(9), 518–525 (1998).
   PubMedGoogle Scholar
• Borczuk AC, Niedt G, Sablay LB et al. Fibrous long-spacing collagen in bacillary angiomatosis. Ultrastruct. Pathol. 22(2), 127–133 (1998).
   PubMed Web of Science ®Google Scholar
• Nayler SJ, Allard U, Taylor L, Cooper K. HHV-8 (KSHV) is not associated with bacillary angiomatosis. Mol. Pathol. 52(6), 345–348 (1999).
   PubMedGoogle Scholar
• International Collaboration on HIVand Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl Cancer Inst. 92, 1823–1830 (2000).
   PubMedGoogle Scholar
• Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. AIDS 13(15), 2105–2111 (1999).
   PubMed Web of Science ®Google Scholar
• Jacobson LP, Yamashita TE, Detels R et al. Impact of potent antiretroviral therapy on the incidence of Kaposi’s sarcoma and non-Hodgkin’s lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 21(Suppl. 1), S34–S41 (1999).
   PubMed Web of Science ®Google Scholar
• Lebbe C, Blum L, Pellet C et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS 12(7), 45–49 (1998).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Anand K, Desai J, Mitnick RJ, Kalkut GE, Hanau LH. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J. Acquir. Immune Defic. Syndr. 21(Suppl. 1), 18–22 (1999).
   Google Scholar
• Diz Dios P, Ocampo Hermida A, Miralles Alvarez C, Vazquez Garcia E, Martinez Vazquez C. Regression of AIDS-related Kaposi’s sarcoma following ritonavir therapy. Oral Oncol. 34(3), 236–238 (1998).
   PubMedGoogle Scholar
• Martinelli C, Zazzi M, Ambu S, Bartolozzi D, Corsi P, Leoncini F. Complete regression of AIDS-related Kaposi’s sarcoma-associated human herpesvirus-8 during therapy with indinavir. AIDS 12(13), 1717–1719 (1998).
   PubMed Web of Science ®Google Scholar
• Murdaca G, Campelli A, Setti M, Indiveri F, Puppo F. Complete remission of AIDS/Kaposi’s sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. AIDS 16(2), 304–305 (2002).
   Google Scholar
• Paparizos VA, Kyriakis KP, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J. Acquir. Immune Defic. Syndr. 30(2), 257–258 (2002).
   PubMed Web of Science ®Google Scholar
• Winceslaus J. Regression of AIDS-related pleural effusion with HAART. Highly active antiretroviral therapy. Int. J. STD AIDS 9(6), 368–370 (1998).
   PubMed Web of Science ®Google Scholar
• Portsmouth S, Stebbing J, Gill J et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. AIDS 17(11), 17–22 (2003).
   PubMed Web of Science ®Google Scholar
• Dezube BJ. Acquired immunodeficiency syndrome-related Kaposi’s sarcoma: clinical features, staging, and treatment. Semin. Oncol. 27(4), 424–430 (2000).
   PubMed Web of Science ®Google Scholar
• Holkova B, Takeshita K, Cheng DM et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi’s sarcoma treated with chemotherapy. J. Clin. Oncol. 19(18), 3848–3851 (2001).
   PubMed Web of Science ®Google Scholar
• Dezube BJ. Management of AIDS-related Kaposi’s sarcoma: advances in target discovery and treatment. Expert Rev. Anticancer Ther. 2(2), 193–200 (2002).
   PubMedGoogle Scholar
• Hengge UR, Ruzicka T, Tyring SK et al. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect. Dis. 2(5), 281–292 (2002).
   PubMed Web of Science ®Google Scholar
• Tulpule A, Yung RC, Wernz J et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi’s sarcoma. J. Clin. Oncol. 16(10), 3369–3374 (1998).
   PubMed Web of Science ®Google Scholar
• Newell M, Milliken S, Goldstein D et al. A Phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi’s sarcoma. Aust. NZ J. Med. 28(6), 777–783 (1998).
   PubMedGoogle Scholar
• Kreuter A, Gambichler T, Schlottmann R, Altmeyer P, Brockmeyer N. Psoriasiform pustular eruptions from pegylated-liposomal doxorubicin in AIDS-related Kaposi’s sarcoma. Acta Derm. Venereol. 81(3), 224 (2001).
   PubMedGoogle Scholar
• Gill PS, Wernz J, Scadden DT et al. Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J. Clin. Oncol. 14(8), 2353–2364 (1996).
   PubMed Web of Science ®Google Scholar
• Rosenthal E, Poizot-Martin I, Saint-Marc T, Spano JP, Cacoub P. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am. J. Clin. Oncol. 25(1), 57–59 (2002).
   PubMed Web of Science ®Google Scholar
• Stewart S, Jablonowski H, Goebel FD et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J. Clin. Oncol. 16(2), 683–691 (1998).
   PubMed Web of Science ®Google Scholar
• Lederman MM. Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS 15(Suppl. 2), S11–S15 (2001).
   PubMedGoogle Scholar
• Nasti G, Errante D, Santarossa S, Vaccher E, Tirelli U. A risk and benefit assessment of treatment for AIDS-related Kaposi’s sarcoma. Drug Saf. 20(5), 403–425 (1999).
   PubMedGoogle Scholar
• Kaplan L, Abrams D, Volberding P. Treatment of Kaposi’s sarcoma in acquired immunodeficiency syndrome with an alternating vincristine–vinblastine regimen. Cancer Treat. Rep. 70(9), 1121–1122 (1986).
   PubMedGoogle Scholar
• Gill P, Rarick M, Bernstein-Singer M et al. Treatment of advanced Kaposi’s sarcoma using a combination of bleomycin and vincristine. Am. J. Clin. Oncol. 13(4), 315–319 (1990).
   PubMed Web of Science ®Google Scholar
• Evans SR, Krown SE, Testa MA, Cooley TP, von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi’s sarcoma: an AIDS Clinical Trials Group clinical study. J. Clin. Oncol. 20(15), 3236–3241 (2002).
   PubMedGoogle Scholar
• Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N. Engl. J. Med. 338(13), 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Uthayakumar S, Bower M, Money-Kyrle J et al. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi’s sarcoma. AIDS 10, 515–519 (1996).
   PubMed Web of Science ®Google Scholar
• White R. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi’s sarcoma. AIDS 11, 1412–1413 (1997).
   PubMedGoogle Scholar
• Esdaile B, Davis M, Portsmouth S et al. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi’s sarcoma. AIDS 16(17), 2344–2347 (2002).
   PubMed Web of Science ®Google Scholar
• Sgadari C, Barillari G, Toschi E et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Med. 8(3), 225–232 (2002).
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Iurlaro M et al. Docetaxel versus paclitaxel for anti-angiogenesis. J. Hematother. Stem Cell Res. 11, 103–108 (2002).
   PubMedGoogle Scholar
• Sgadari C, Toschi E, Palladino C et al. Mechanism of paclitaxel activity in Kaposi’s sarcoma. J. Immunol. 165(1), 509–517 (2000).
   PubMed Web of Science ®Google Scholar
• Saville MW, Lietzau J, Pluda JM et al. Treatment of HIV-associated Kaposi’s sarcoma with paclitaxel. Lancet 346, 26–28 (1995).
   PubMed Web of Science ®Google Scholar
• Welles L, Saville MW, Lietzau J et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J. Clin. Oncol. 16, 1112–1121 (1998).
   PubMed Web of Science ®Google Scholar
• Gill PS, Tulpule A, Espina BM et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. J. Clin. Oncol. 17, 1876–1883 (1999).
   PubMed Web of Science ®Google Scholar
• Tulpule A, Groopman J, Saville MW et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 95(1), 147–154 (2002).
   PubMed Web of Science ®Google Scholar
• Stebbing J, Wildfire A, Portsmouth S et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi’s sarcoma: clinical and angiogenic correlations. Ann. Oncol. 14(11), 1660–1666 (2003).
   PubMed Web of Science ®Google Scholar
• Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi’s sarcoma. AIDS 13, 283–284 (1999).
   PubMed Web of Science ®Google Scholar
• Menke DM, Chadbum A, Cesarman E et al. Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of castleman disease at low risk for HIV infection. Am. J. Clin. Pathol. 117(2), 268–275 (2002).
   PubMedGoogle Scholar
• Rallidis LS, Zolindaki MG, Manioudaki HS, Laoutaris NP, Velissaridou AH, Papasteriadis EG. Prognostic value of C-reactive protein, fibrinogen, interleukin-6, and macrophage colony stimulating factor in severe unstable angina. Clin. Cardiol. 25(11), 505–510 (2002).
   PubMedGoogle Scholar